Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (BHC) delivers innovative healthcare solutions across gastroenterology, dermatology, and eye health through brands like Bausch + Lomb and Salix Pharmaceuticals. This page provides investors and industry professionals with a comprehensive repository of official company announcements and market-relevant updates.
Key resources include: earnings reports, regulatory filings, product launch announcements, and partnership developments. All content is sourced directly from BHC’s verified communications to ensure accuracy and timeliness.
Regularly updated with press releases spanning therapeutic advancements, financial results, and operational milestones. Bookmark this page to monitor BHC’s strategic initiatives within the global pharmaceutical landscape.
Bausch + Lomb announced that it will present data on its Bausch + Lomb INFUSE silicone hydrogel daily disposable contact lenses at the virtual Global Specialty Lens Symposium from Jan. 21-23, 2021. During this event, Bausch + Lomb will also discuss fitting efficiencies for its Zenlens™ scleral lenses. A survey reported that 97% of patients experienced crisp, clear vision with INFUSE lenses, and 94% agreed they help maintain moisture. Two poster presentations will focus on the lenses' impact on tear film protein and water stability.
Bausch Health announced the publication of a Phase 2 study in Cornea, demonstrating that NOV03, an investigational treatment for Dry Eye Disease (DED) related to Meibomian gland dysfunction, met its primary efficacy endpoint. The study enrolled 336 patients and exhibited significant improvements in corneal staining and symptoms like dryness and burning. Additionally, the first of two Phase 3 studies evaluating NOV03 has been fully enrolled with 599 participants. These developments position NOV03 as a potential first-in-class treatment for millions suffering from symptomatic DED.
Bausch Health Companies Inc. (BHC) is set to provide a preliminary update on Q4 and full-year 2020 financial results during a chat at the J.P. Morgan Healthcare Conference on Jan. 13, 2021. The company anticipates Q4 revenue exceeding $2.20 billion and full-year revenue surpassing $8.00 billion. Bausch Health projects over $1 billion in operational cash flow for 2020 and highlights a $900 million debt repayment. Full financial results will be released next month.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that CEO Joseph C. Papa will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:00 a.m. ET. A live webcast and audio archive will be accessible on the company's Investor Relations page. Bausch Health focuses on improving lives through a range of healthcare products, primarily in eye health, gastroenterology, and dermatology. More details are available on their website.
Bausch Health Companies (NYSE/TSX: BHC) announced a new indication for DEXAVEN (dexamethasone phosphate) solution for injection in Poland. This approval allows treatment for COVID-19 in adults and adolescents who require oxygen therapy. The corticosteroid DEXAVEN helps reduce inflammation. CEO Thomas J. Appio expressed satisfaction with this development as it provides additional treatment options for patients. However, it is important to note that dexamethasone products are not FDA-approved for COVID-19 treatments in the United States.
Bausch Health announced plans to repay approximately $900 million of debt in 2020, including $275 million on Dec. 31, 2020. This repayment will leave the company with no debt maturities or mandatory amortization payments until 2024. Bausch Health's total debt repayment for the fourth quarter of 2020 will be around $480 million, reflecting strong cash flow recovery despite COVID-19's impacts. CEO Joseph C. Papa emphasized the commercial team's resilience and effective cash conservation strategies.
Bausch Health Companies (NYSE/TSX: BHC) announced the initiation of the second Phase 3 study for NOV03, an investigational treatment for Dry Eye Disease (DED) linked to Meibomian gland dysfunction. This study follows the successful enrollment of the first Phase 3 study, which is 85% complete. NOV03, using patented EyeSol® technology, showed positive results in a Phase 2 study, significantly improving corneal staining and symptoms in patients. If approved, it may become the first pharmaceutical therapy for U.S. patients suffering from DED associated with MGD.
Bausch Health Companies Inc. (BHC) has priced an upsized offering of $2.0 billion in senior notes, consisting of 5.000% notes due 2029 and 5.250% notes due 2031. The additional $250 million will facilitate the conditional redemptions of existing €1.5 billion Euro Notes and $233 million 5.50% Notes, eliminating any note maturities until 2024. The offering aims to strengthen the company's financial position, contingent upon specific financing conditions.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a $1.75 billion offering of new senior notes due in 2029 and 2031. Proceeds will fund the full redemption of €1.5 billion 4.50% Senior Notes due 2023 and cover related fees. The Notes will not be registered and will be offered only to qualified institutional buyers in the U.S. and to non-U.S. persons abroad. The redemption is conditional on completing debt financings of at least $1.75 billion. The transaction is expected to close in Q4 2020, subject to market conditions.
Bausch Health Companies (NYSE/TSX: BHC) announced new investigational in vitro data indicating that its eye drops, LUMIFY and BESIVANCE, effectively inactivate SARS-CoV-2, the virus responsible for COVID-19. These findings were presented at the Ocular Microbiology and Immunology Group's annual meeting on Nov. 13, 2020. In testing, LUMIFY and BESIVANCE showed complete inactivation of the virus at various contact times. However, the clinical relevance of these findings is uncertain, and neither product is approved for treating COVID-19 in humans.
